Divi's Laboratories has reported results for fourth quarter (Q4) and year ended March 31, 2023.
The company has reported 63.90% fall in its net profit at Rs 318.79 crore for the quarter under review as compared to Rs 882.96 crore for the same quarter in the previous year. Total income of the company decreased by 22.44% at Rs 1,974.32 crore for Q4FY23 as compared to Rs 2,545.54 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 64.12% fall in its net profit at Rs 320.97 crore for fourth quarter ended March 31, 2023 as compared to Rs 894.64 crore for the same quarter in the previous year. Total income of the company decreased by 21.55% at Rs 2,016.92 crore for Q4FY23 as compared to Rs 2,570.83 crore for the corresponding quarter previous year.
For the year ended March 31, 2023, the company has reported 38.68% fall in its net profit at Rs 1,808.15 crore as compared to Rs 2,948.54 crore for the previous year. Total income of the company decreased by 11.31% at Rs 7,974.31 crore for year under review as compared to Rs 8,991.08 crore for year ended March 31, 2022.
For the year ended March 31, 2023, on the consolidated basis, the company has reported 38.41% fall in its net profit of Rs 1,823.38 crore as compared to Rs 2,960.45 crore for the previous year. Total income of the company decreased by 10.60% at Rs 8,112.17 crore for year under review as compared to Rs 9,073.70 crore for year ended March 31, 2022.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1837.30 |
Dr. Reddys Lab | 1370.60 |
Cipla | 1495.05 |
Lupin | 2252.40 |
Zydus Lifesciences | 981.55 |
View more.. |